Comparative study of Mg/Al- and Zn/Al-layered double hydroxide-perindopril erbumine nanocomposites for inhibition of angiotensin-converting enzyme.
The intercalation of a drug active, perindopril, into Mg/Al-layered double hydroxide for the formation of a new nanocomposite, PMAE, was accomplished using a simple ion exchange technique. A relatively high loading percentage of perindopril of about 36.5% (w/w) indicates that intercalation of the active took place in the Mg/Al inorganic interlayer. Intercalation was further supported by Fourier transform infrared spectroscopy, and thermal analysis shows markedly enhanced thermal stability of the active. The release of perindopril from the nanocomposite occurred in a controlled manner governed by pseudo-second order kinetics. MTT assay showed no cytotoxicity effects from either Mg/Al-layered double hydroxide or its nanocomposite, PMAE. Mg/Al-layered double hydroxide showed angiotensin-converting enzyme inhibitory activity, with 5.6% inhibition after 90 minutes of incubation. On incubation of angiotensin-converting enzyme with 0.5 μg/mL of the PMAE nanocomposite, inhibition of the enzyme increased from 56.6% to 70.6% at 30 and 90 minutes, respectively. These results are comparable with data reported in the literature for Zn/Al-perindopril.
Department of Chemistry, Faculty of Science, Universiti Putra Malaysia, Serdang, Selangor, Malaysia.
Samer Hasan
SH
Hussein Al Ali
Mothanna
M
Al-Qubaisi
Mohd Zobir
MZ
Hussein
Maznah
M
Ismail
Zulkarnain
Z
Zainal
Muhammad Nazrul
MN
Hakim
D000327:Adsorption; D000536:Aluminum Hydroxide / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D006626:Hippurates / Q000032:analysis / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008276:Magnesium Hydroxide / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D053761:Nanocomposites / Q000737:chemistry*; D009842:Oligopeptides / Q000032:analysis / Q000378:metabolism; D007703:Peptidyl-Dipeptidase A / Q000737:chemistry / Q000378:metabolism; D020913:Perindopril / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D013055:Spectrophotometry, Infrared; D014961:X-Ray Diffraction; D015032:Zinc / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology
D000806:Angiotensin-Converting Enzyme Inhibitors; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D006626:Hippurates; D009842:Oligopeptides; C010980:hippuryl-histidyl-leucine; C013591:aluminum hydroxide, magnesium hydroxide, drug combination; D000536:Aluminum Hydroxide; D007703:Peptidyl-Dipeptidase A; D015032:Zinc; D008276:Magnesium Hydroxide; C030514:hippuric acid; D020913:Perindopril